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The bone remodeling and homeostasis are mainly controlled by the receptor-activator of nuclear factor κB 
(RANK), its ligand RANKL, and the soluble decoy receptor osteoprotegerin (OPG) pathway. While there is a 
strong association between osteoporosis and skeletal muscle dysfunction, the functional relevance of a particular 
biological pathway that synchronously regulates bone and skeletal muscle physiopathology remains elusive. Our 
recent article published in the American Journal of Physiology (Cell Physiology) showed that RANK is also 
expressed in fully differentiated C2C12 myotubes and skeletal muscles. We used the Cre-Lox approach to 
inactivate muscle RANK (RANKmko) and showed that RANK deletion preserves the force of denervated 
fast-twitch EDL muscles. However, RANK deletion had no positive impact on slow-twitch Sol muscles. In 
addition, denervating RANKmko EDL muscles induced an increase in the total calcium concentration ([CaT]), 
which was associated with a surprising decrease in SERCA activity. Interestingly, the levels of STIM-1, which 
mediates Ca2+ influx following the depletion of SR Ca2+ stores, were markedly higher in denervated RANKmko 
EDL muscles. We speculated that extracellular Ca2+ influx mediated by STIM-1 may be important for the 
increase in [CaT] and the gain of force in denervated RANKmko EDL muscles. Overall, these findings showed for 
the first time that the RANKL/RANK interaction plays a role in denervation-induced muscle atrophy and 
dysfunction. 
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Introduction 
Bone remodeling is an essential process for maintaining 
bone homeostasis throughout the life of an individual. It is 
under the control of local and systemic factors that 
orchestrate osteoblast/osteoclast activation [1-4]. RANK, the 
receptor-activator of RANKL, and the OPG triad 
(RANK/RANKL/OPG) play important roles in fine-tuning 
the activity of these two bone cell types. RANKL is mainly 
expressed by bone marrow mesenchymal stromal cells and 
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osteoblasts [5-6]. The binding of RANKL to RANK on 
osteoclast precursors trimerizes its receptor and induces 
osteoclast differentiation and activation, resulting in bone 
resorption. RANK knockout impairs osteoclastogenesis and 
induces osteopetrosis, while the overproduction of RANKL 
induces osteoporosis [7, 8]. OPG, the third protagonist, is 
mainly produced by bone marrow mesenchymal stromal cells 
and osteoblasts and exerts an inhibitory effect on the 
osteoclastic process. OPG has a high affinity for RANKL 
and inhibits the RANKL/RANK interaction and subsequent 
bone degradation. In addition to RANKL, OPG serves as a 
low affinity decoy receptor for TRAIL. Pre-clinical studies 
have suggested that this interaction increases cell survival by 
blocking the apoptotic effects of the RANKL/RANK 
interaction [9, 10]. The fact that the overexpression of OPG or 
an exogenous OPG treatment [11] in mice results in 
osteopetrosis and that OPG-null mice are osteoporotic are 
testimony to the physiological importance of OPG [11].  
Clinical studies have clearly shown that there is an 
association between osteoporosis and muscle atrophy and 
that the worsening of these conditions happens in tandem [12, 
13]. While bones and skeletal muscles are closely related and 
are mechanically linked, the possibility of dynamic 
Figure 1. Schematic and hypothetical representation depicting the function of RANK in skeletal muscle. The action potential is conducted 
into the interior of the muscle cell along the T-tubules where DHPR, a voltage sensor protein, triggers Ca2+ release from the SR through RyR and 
muscle contraction. Once released, SERCA pumps back the Ca2+ into the SR allowing muscle relaxation and preparing muscle for the next 
contraction. In bone cells, RANKL/RANK interaction is important for SERCA activation, [Ca2+]i oscillations and osteoclastogenesis. In skeletal 
muscle, a rise in [Ca2+]i would stimulate calcineurin, a calcium dependent protein phosphatase that subsequently dephosphorylates NFATc1 and 
promotes a slower muscle phenotype. Muscle specific RANK deletion (RANKmko) reduces SERCA activity but protects against sciatic 
denervation-induced muscle dysfunction and favors a fast-twitch phenotype. We speculate that STIM-1/Orai-1 complex would compensate for 
the lack of SERCA activity, refilling Ca2+ stores and improving muscle function in atrophied and denervated RANKmko EDL muscles. Although the 
complete and precise role of muscle RANK remains poorly understood, our article in American Journal of Physiology (Cell physiology) shows 
that muscle RANK is an important regulator of Ca2+ storage, muscle phenotype, and muscle function in normal and pathological conditions. 
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molecular cross-talk between these tissues and a common 
signaling pathway that can efficiently control them has been 
underappreciated to date. Since the RANK/RANKL/OPG 
pathway is the most important cytokine network involved in 
bone biology and diseases, we postulated that this bone 
pathway is also involved in muscle atrophy and dysfunction. 
We first showed by Western blotting and confocal 
microscopy that C2C12 myotubes and fully differentiated 
skeletal muscles express RANK on the membranes of fast 
and slow-twitch myofibers [14]. Based on the protective effect 
of RANK deletion on bone mass [15], we next postulated that 
selective muscle RANK deletion preserves muscle mass and 
function and favors a fast-twitch phenotype following 
denervation.   
Muscle phenotype and RANK  
Skeletal muscles are primarily composed of four muscle 
fiber types: type I fibers (slow and oxidative), type IIa fibers 
(fast and oxidative), and type IIx and IIb fibers (fast and 
glycolytic). The function largely dictates the phenotype and 
composition of each skeletal muscle. For example, the Sol 
muscle, a postural muscle, is largely composed of slow 
oxidative type I fibers while the EDL muscle, a phasic 
muscle, is almost exclusively composed of fast-twitch fibers 
[16]. These two muscles encompass the two extremes of the 
phenotypic spectrum of the skeletal muscle contractile 
apparatus. Type I fibers play an important role in maintaining 
the body in an upright position, while type IIb and IIx fibers 
are responsive during movement and physical activity. Type 
IIa fibers are a hybrid of type I and type IIb fibers and can 
perform short or prolonged exercises. Specific exercises, 
immobilization, unloading, denervation, muscle diseases, or 
glucocorticoid treatments affect all four muscle fiber 
phenotypes to different degrees. For instance, decreases in 
mechanical loading and neuromuscular activity favor muscle 
atrophy and a conversion of muscle fiber phenotypes from 
slow to fast [17]. Functional muscle overload causes a gain in 
muscle mass while prolonged exercise leads to the 
transformation of pre-existing fast-twitch muscle fibers to a 
slow-twitch oxidative phenotype. Type IIb fibers, the most 
powerful fibers, are converted to oxidative phenotype fibers 
(type I or IIa) and disappear through a necrotic process 
during myopathies, aging, and glucocorticoid treatments [18, 
19]. Intracellular/cytosolic Ca2+ ([Ca2+]i) fluctuations play a 
crucial role in the maintenance and adaptation of muscle 
phenotypes. The increase in [Ca2+]i is caused by a Ca2+ influx 
from the extracellular space and/or Ca2+ release from [Ca2+]i 
stores. The SR is the major releasable [Ca2+]i store. Ca2+ 
channels and pumps maintain a steep Ca2+ concentration 
gradient between different cell compartments. Generally 
speaking, the spatial pattern of increased free [Ca2+]i at rest 
induces the activation of calmodulin and downstream Ca2+ 
decoders, namely calcineurin and CaMKII [20]. These two 
decoders modify gene transcription by activating 
transcription factors such as NFATc1 and MEF2 and 
transcription modulators such as HDAC and PGC-
promoting the slow myofiber phenotype [21] (Figure 1). 
Interestingly, the increase in [Ca2+]SR is essential to activate 
NFATc1, while extracellular Ca2+ is required to maintain its 
activation [22] and to replenish [Ca2+]i stores [23]. Since over 
97% of [Ca2+]i is stored in the SR at rest, the measurement of 
total Ca2+ ([CaT]) is an estimate of [Ca2+]SR content [24]. We 
used Cre-Lox technology to inactivate muscle RANK and 
found that the selective deletion of muscle RANK 
(RANKmko) decreases [CaT] in fast-twitch EDL muscles but 
not in Sol muscles, when compared to RANKflox/flox 
(RANKf/f) muscles. However, sciatic denervation markedly 
increased [CaT] in RANKmko EDL muscles. In addition, we 
discovered that denervated RANKmko EDL muscles are 
smaller, more fatigable, and surprisingly stronger than 
RANKf/f EDL muscles. Since force production is usually 
proportional to muscle size, we hypothesized that the 
increase in [CaT], i.e., [Ca2+]SR at rest, would favor Ca2+ 
release, increasing free [Ca2+]i and thereby the specific force 
of denervated RANKmko EDL muscles. The phenotypic 
profiles, which are consistent with these observations, 
showed a lower proportion of slow-twitch type I and 
fast-twitch type IIx fibers and a higher proportion of 
fast-twitch type IIa/IIb fibers in RANKmko EDL muscles 
relative to RANKf/f EDL muscles. However, muscle fatigue 
was significant and could not be explained by the modest 
changes in myofiber type in sham and denervated RANKmko 
EDL muscles. In this context, it would be highly relevant to 
determine whether muscle RANK deletion influences 
mitochondria Ca2+ uptake, another important regulator of 
[Ca2+]i and energy production. Our results showed for the 
first time that muscle RANK is an important regulator of 
Ca2+ storage, muscle phenotype, and muscle fatigue in 
normal and pathological conditions.  
Calcium signaling, RANK, and skeletal muscle  
Muscle contraction involves the depolarization of the 
transverse-tubular system and activation of DHPRs, which in 
turn open RYR1 receptors adjacent to the SR membrane [25]. 
This results in the rapid efflux of large amounts of Ca2+ into 
the cytoplasm and the binding of Ca2+ to troponin C, causing 
the formation of cross-bridges between actin and myosin, the 
shortening of the sarcomere, and force development [26]. To 
avoid permanent contraction and allow muscle relaxation, 
Ca2+ is in part pumped back into the SR by an ATP-dependent 
Ca2+ pump called SERCA. Ca2+ reuptake into the SR is mainly 
controlled by the fast-twitch SERCA-1a and slow-twitch 
SERCA-2a isoforms in myofibers. The movement of Ca2+ is 
reduced when PLN is associated with SERCA. Under 
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β-adrenergic stimulation, like the stress hormones adrenaline 
and noradrenaline, or sympathomimetic drugs, the 
phosphorylation-dependent dissociation of PLN by PKA 
increases SERCA activity and Ca2+ movement, enhancing 
skeletal muscle and heart functions (Figure 1). Alternatively, 
PLN deletion increases cardiac output by decreasing the time 
to peak pressure and the half-relaxation time [27], indicating 
that efficient Ca2+ mobilization and the disinhibition of 
SERCA are prerequisites for powerful contractions. 
Conversely, dysfunctional SERCA expression and activity 
impair [Ca2+]i homeostasis, reducing the force production and 
power output of skeletal and cardiac muscles [28, 29]. This is 
particularly true for fast-twitch muscles, like in dystrophic 
EDL muscles where Ca2+ handling is altered with the 
expression of the slow isoform of SERCA-2a [30]. Increased 
Ca2+ influx thus activates proteolytic pathway, which in turn 
causes even greater Ca2+ influx, giving rise to a possible 
vicious pathological cycle in dystrophic muscles [31]. 
Interestingly, the overexpression of SERCA mitigates 
muscular dystrophy and rescues cardiac function in a model of 
pressure overload, highlighting the importance of SERCA in 
muscle performance and disease [32, 33]. In our paper, we 
report a number of intriguing and challenging observations, 
including the fact that RANK deletion in denervated EDL 
muscles increases [CaT] and specific force and decreases 
SERCA activity. This apparent discrepancy between the 
increase in [CaT] and the decrease in SERCA activity may be 
due to an alternative source of Ca2+ refilling the SR. Indeed, 
extracellular Ca2+ and SOCE are important for optimal muscle 
force production, while SOCE inhibition is associated with a 
decrease in contractile properties [34]. More specifically, 
Orai-1 Ca2+ channels are key sensors and major contributors to 
Ca2+ entry into the SR via an interplay with STIM-1. When SR 
Ca2+ stores are depleted, STIM-1 activates Orai-1 to refill the 
stores [35]. Additionally, Stiber et al. (2008) demonstrated 
that STIM-1+/+ myotubes maintain full Ca2+ stores whereas 
STIM-1-/- myotubes fail to refill SR Ca2+ stores following 
chronic stimulations [36]. Interestingly, we showed that 
denervated RANKmko EDL muscles have a markedly higher 
STIM-1 content. Since the increase in [CaT] and the decrease 
in SERCA activity in denervated RANKmko EDL muscles are 
somewhat irreconcilable, we proposed that STIM-1 and 
Orai-1 compensate for the lack of SERCA activity, refilling 
SR Ca2+ stores in the absence of muscle RANK. 
RANKL/RANK interactions and intracellular signaling 
networks in bone and skeletal muscle 
In bone, RANKL/RANK interactions activate TRAF-6, 
which then induces the activation of downstream signaling 
molecules and [Ca2+]i oscillations [37]. SERCA is essential for 
[Ca2+]i oscillations and plays a critical role in 
osteoclastogenesis [38]. It has recently been reported that 
SERCA-2a heterozygote mice (SERCA2a+/-) present defects 
in osteoclast differentiation and the suppression of 
RANKL-induced Ca2+ oscillations [39]. Tmem64, a positive 
modulator of osteoclast differentiation, regulates 
RANKL-induced Ca2+ signaling via SERCA2a [40]. In 
addition to SERCA, Ca2+ oscillations may partly derive from 
extracellular Ca2+. Gadolinium, a specific SOCE blocker, 
abolishes RANKL-induced Ca2+ oscillations [41] while the 
knockdown of STIM-1 significantly reduces the frequency of 
RANKL-induced Ca2+ oscillations, indicating that SOCE and 
RANK communicate. TRP channels are also candidates for 
the Ca2+ influx involved in RANKL-induced Ca2+ 
oscillations [42]. Chamoux et al. (2010) showed that RANKL 
induces a significant increase in [Ca2+]i from outside, 
presumably through the TRPV-5 Ca2+ channel. While an 
elaborate approach has been proposed to elucidate how 
RANKL/RANK induces Ca2+ oscillations in bone cells, the 
importance of this pathway in skeletal muscle is extremely 
limited. Our work reported in the American Journal of 
Physiology (Cell Physiology) was, to our knowledge, the 
first attempt to assign a regulatory role for RANKL/RANK 
interactions on SERCA activity in bone and muscle cells [14]. 
The identification of downstream effectors of muscle RANK 
will be an important step in determining precisely how the 
RANKL/RANK interaction modulates SERCA activity. 
Bioinformatic approaches may eventually be required to 
improve our understanding of the cell signaling network and 
to determine how the RANKL/RANK interaction regulates 
SERCA activity and possibly other Ca2+ channels in skeletal 
muscles. 
Future directions and perspectives 
We convincingly show in another publication in the 
American Journal of Pathology (2015) [43] that OPG-Fc (OPG 
fused to immunoglobulin Fc) completely restores the 
function of dystrophic EDL muscles and significantly 
improves the function of Sol and diaphragm muscles. OPG 
treatments also provide significant protection against 
eccentric-contraction-induced muscle damage. As observed 
with OPG-treated dystrophic mice, muscle RANK deletion 
preferentially protects fast-twitch fibers. It is important to 
note that fast-twitch fibers are essential for brief and 
powerful contractions. They are predominantly affected 
directly or indirectly in aging and in several forms of muscle 
disease and chronic illness, including diabetes, congestive 
heart failure, renal failure, chronic heart disease, and chronic 
obstructive pulmonary disease. Our results clearly show that 
the role of the RANK/RANKL/OPG pathway extends well 
beyond bone remodeling and osteoporosis and that skeletal 
muscles and other tissues may share the 
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RANK/RANKL/OPG pathway as a common denominator. 
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